Stephen V Liu/X
Jun 8, 2025, 16:34
Stephen V Liu Shared ORCHARD Study Results on Osimertinib Plus Necitumumab in EGFR-Mutated NSCLC Published in JCO
Stephen V Liu, Associate Professor of Medicine at Georgetown University, shared a post on X:
“Results from Osimertinib + Necitumumab module of phase II ORCHARD study published in JCO.
Patients with EGFR-Mutated NSCLC with progression on osi and EGFR amplification or secondary EGFR mt received Osimertinib 80mg + Necitumumab D1/8 q21d. RR 11%, PFS 4m, OS 11.4m, 53% had G3+ AE.”
Title: ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor–Mutated Advanced Non–Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib
Journal: JCO
Authors: Jonathan W. Riess, Adrianus J. de Langen, Santiago Ponce, Sarah B. Goldberg, Zofia Piotrowska, Jonathan W. Goldman, Xiuning Le, Byoung Chul Cho, Yasuto Yoneshima, Helen Ambrose, Riccardo Cavazzina, Kwan Ho Tang, James Lau, Helena A. Yu
Adrianus J de Langen
Byoung Chul Cho
cancer
EGFR-mutated NSCLC
Georgetown University
Helen Ambrose
Helena A. Yu
James Lau
Jonathan W. Goldman
Jonathan W. Riess
Kwan Ho Tang
Necitumumab
OncoDaily
Oncology
ORCHARD
osimertinib
Riccardo Cavazzina
Santiago Ponce
Sarah B. Goldberg
Stephen V Liu
Xiuning Le
Yasuto Yoneshima
Zofia Piotrowska
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 8, 2025, 16:27
Jun 8, 2025, 16:24
Jun 8, 2025, 10:36